Matthias Peipp

This paper explores using anti-TSHR autoantibodies to create bispecific antibodies and CAR T cells for treating poorly differentiated thyroid cancer, showing potent in vitro and in vivo activity.

The paper tests a CD19xCD3 bispecific T cell engager in a mouse model of pemphigoid disease and finds it induces remission in 45% of treated mice.

This paper introduces a multifunctional fusion protein that enables efficient ex vivo expansion of NK cells from various sources and enhances their cytotoxic activity against tumor cells.

This study develops a human immune system mouse model for EBA, demonstrating that PDK1 inhibition reduces skin inflammation and immune cell activation.

This paper evaluates a novel Fc-optimized antibody drug conjugate targeting CD7, showing potent anti-leukemia activity in preclinical T-ALL models.

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

This study evaluates the efficacy of CD38 and CD20 IgG1/IgA2 antibodies in mediating myeloid cell-mediated killing of B-ALL, showing enhanced activity with CD47/SIRPα blockade.

This study shows RTX-IgG2 enhances phagocytosis of B-cell lymphoma cells by reducing CD47 expression and promoting apoptosis, improving the efficacy of antibody-based therapies.